X
  1. Bomback AS, Fervenza FC. Membranous Nephropathy: Approaches to Treatment. Am J Nephrol. 2018;47 Suppl 1:30-42.
  2. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-97.
  3. Menon S, Valentini RP. Membranous nephropathy in children: clinical presentation and therapeutic approach. Pediatr Nephrol. 2010;25(8):1419-28.
  4. Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12(3):502-17.
  5. Korbet SM. Treatment of primary FSGS in adults. J Am Soc Nephrol. 2012;23(11):1769-76.
  6. Johnson RJ, Feehally J, Floege J. Comprehensive Clinical Nephrology. 5th ed. Philadelphia, PA: Elsevier Saunders; 2015.
  7. Lewis JB, Neilson EG. Glomerular diseases. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, et al, eds. Harrison’s Principles of Internal Medicine. 19th ed. New York, NY: McGraw Hill Medical Publishing; 2015:1831-1850.
  8. Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal Change Disease. Clin J Am Soc Nephrol. 2017;12(2):332-45.
  9. Fervenza FCSS. Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis. https://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoproliferative-glomerulonephritis. Accessed July 2018.
  10. Kidney Disease Improving Global Outcomes (KDIGO). Glomerulonephritis. http://kdigo.org/home/glomerulonephritis-gn/. 2012. Accessed July 12, 2018.
  11. Acthar® Gel (repository corticotropin injection) [prescribing information]. Bedminster, NJ: ARD LLC; 2019.
  12. Fervenza FCSS. Evaluation and treatment of membranoproliferative glomerulonephritis. https://www.uptodate.com/contents/evaluationand-treatment-of-membranoproliferative-glomerulonephritis. Accessed July 2018. Kopel T, et al. Dense deposit disease (membranoproliferative glomerulonephritis type II). http://ultramedica.net/Uptodate21.6/contents/UTD.htm?3/26/3498?source=related_link. Accessed July 2018.
  13. Kopel T, et al. Dense deposit disease (membranoproliferative glomerulonephritis type II). http://ultra- medica.net/Uptodate21.6/contents/UTD.htm?3/26/3498?source=related_link. Accessed July 2018.
  14. Orapred ODT® (prednisolone sodium phosphate orally disintegrating) tablets [prescribing information]. Atlanta, GA: Shionogi Pharma, Inc; 2010.
  15. Glucocorticoid Pharmacology. Tulane University. http://tmedweb.tulane.edu/pharmwiki/doku.php/glucocorticoid_pharmacology. Accessed August 2018.
  16. Imuran® (azathioprine) tablets [prescribing information]. San Diego, CA: Prometheus Laboratories, Inc; 2011.
  17. Leukeran® (chlorambucil) tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline LLC; 2006.
  18. Shetty N. Immunology: Introductory Textbook: New Age International(P) Limited, Publishers; 2005.
  19. Cytoxan® (cyclophosphamide) injection [prescribing information]. Deerfield, IL: Baxter Healthcare; 2013.
  20. Gengraf® (cyclosporine) capsules USP [prescribing information]. North Chicago, IL: AbbVie, Inc; 2017.
  21. Prograf® (tacrolimus) injection [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc; 2015.
  22. CellCept® (mycophenolate mofetil) injection [prescribing information]. Nutley, NJ: Roche Laboratories, Inc; 2015.
  23. Rituxan® (rituximab) injection [prescribing information]. San Francisco, CA: Genentech, Inc; 2016.
  24. Gong R. The Renaissance of Corticotropin Therapy in Proteinuric Nephropathies. Nat Rev Nephrol. 2011;8(2):122–128
  25. Abbas F, El Kossi M, Jin JK, Sharma A, Halawa A. Recurrence of primary glomerulonephritis: Review of the current evidence. World J Transplant. 2017 Dec 24; 7(6): 301–316.
  26. Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney International. 2017; 91: 304–314.
  27. Kidney Disease Improving Global Outcomes (KDIGO). Kidney Transplant Recipient. https://kdigo.org/guidelines/transplant-recipient. 2009. Accessed March 2019.
  28. Alhamad T, Dieck JM, Younus U, et al. ACTH gel in resistant focal segmental glomerulosclerosis after kidney transplantation. Transplantation. 2019;103:202–209.
  29. Salvadori M, Tsalouhos A. Recurrence of Primary Glomerulonephritis after Renal Transplantation. Juniper Publishers Inc. December 14 2017.
  30. Soliris® (eculizumab) injection, for intravenous use [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc; 2018.
  31. National Institute for Health and Care Excellence. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab. Evidence Summary. 2015. https://www.nice.org.uk/advice/esuom44/chapter/Full-evidence-summary. Accessed March 2019.
  32. McKenzie PE Taylor AE Woodroffe AJ Seymour AE Chan YL Clarkson AR. Plasmapheresis in glomerulonephritis. Clin Nephrol. 1979; 12: 97– 108.